MedTech Start-up SurgMark announces FDA 510(k) Clearance for Biocompatible SchurSign® Tissue Marker
SurgMark GmbH today announced that the U.S. Food & Drug Administration (FDA) has issued a 510(k) premarket notification for its...
top of page
NEWS
- 13. Nov. 2023
- 1 Min.
SurgMark at MEDICA/COPAMED 2023
Biomaterial in breast cancer diagnostics: Hamburg-based start-up SurgMark presents SchurSign® Tissue Marker at MEDICA/COPAMED 2023...
- 1. Nov. 2023
- 2 Min.
Revolutionizing Breast Cancer Diagnostics: SurgMark Introduces SchurSign® Tissue Marker at MEDICA/CO
The Future of Early Detection Unveiled In a significant stride towards redefining breast cancer diagnostics, Hamburg-based start-up...
- 24. Apr. 2023
- 2 Min.
Medical technology start-up SurgMark aims to enter the US market
Press Release Medical technology start-up SurgMark aims to enter the US market FDA Approval Sought for Biocompatible SchurSign® Tissue...
- 1. Dez. 2021
- 1 Min.
Production of the marker started
In December 2021, production of the marker could be started under GMP and cleanroom conditions. The first markers will be produced for...
- 29. Sept. 2021
- 1 Min.
Dr Christine König elected to the BGB Board of Life Science Nord e.V.
Dr Christine König was elected by the members to the BGB Board of Life Science Nord (LSN) e.V. as treasurer. LSN has over 270 members...
bottom of page